Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with higher-risk MDS (IPSS-R score of 4 or higher).
- Your MDS cells must have a specific change in the IDH2 gene, confirmed by a special test.
- You cannot have had any prior treatment for MDS or AML (except hydroxyurea to lower white blood cells, and some other limited treatments).
- You must be able to take pills and have adequate liver and kidney function.
- You must be 18 years or older and have a good performance status (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Hear when a new Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.